Revenue Recognition - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Disaggregation of Revenue [Line Items]
Net revenue	$ 862,684	$ 784,513	$ 2,381,400	$ 2,204,441
Affordable Medicines
Disaggregation of Revenue [Line Items]
Net revenue	547,109	460,741	1,460,259	1,308,874
Affordable Medicines \| Subtotal dosage forms
Disaggregation of Revenue [Line Items]
Net revenue	542,194	454,453	1,442,412	1,299,451
Affordable Medicines \| Oral solid
Disaggregation of Revenue [Line Items]
Net revenue	207,517	180,460	553,789	537,675
Affordable Medicines \| Transdermal
Disaggregation of Revenue [Line Items]
Net revenue	68,066	47,599	209,067	131,372
Affordable Medicines \| Auto-Injector
Disaggregation of Revenue [Line Items]
Net revenue	65,163	78,940	169,289	193,694
Affordable Medicines \| Injectable
Disaggregation of Revenue [Line Items]
Net revenue	53,805	54,368	160,526	123,802
Affordable Medicines \| Biosimilar
Disaggregation of Revenue [Line Items]
Net revenue	77,710	17,009	129,139	70,797
Affordable Medicines \| Oral liquid
Disaggregation of Revenue [Line Items]
Net revenue	9,092	16,415	31,555	57,842
Affordable Medicines \| Other dosage forms
Disaggregation of Revenue [Line Items]
Net revenue	60,841	59,662	189,047	184,269
Affordable Medicines \| International
Disaggregation of Revenue [Line Items]
Net revenue	4,915	6,288	17,847	9,423
Specialty
Disaggregation of Revenue [Line Items]
Net revenue	150,262	125,240	432,822	361,580
Specialty \| Subtotal therapeutic classes
Disaggregation of Revenue [Line Items]
Net revenue	148,774	125,240	431,334	361,080
Specialty \| Central nervous system
Disaggregation of Revenue [Line Items]
Net revenue	96,177	77,631	274,904	228,666
Specialty \| Hormonal / allergy
Disaggregation of Revenue [Line Items]
Net revenue	43,148	37,685	121,179	107,302
Specialty \| Other therapeutic classes
Disaggregation of Revenue [Line Items]
Net revenue	9,449	9,924	35,251	25,112
Specialty \| License agreement
Disaggregation of Revenue [Line Items]
Net revenue	1,488	0	1,488	500
AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	165,313	198,532	488,319	533,987
AvKARE \| Distribution
Disaggregation of Revenue [Line Items]
Net revenue	92,905	96,216	268,984	300,774
AvKARE \| Government label
Disaggregation of Revenue [Line Items]
Net revenue	53,385	87,755	163,541	183,313
AvKARE \| Institutional
Disaggregation of Revenue [Line Items]
Net revenue	10,012	5,853	31,943	26,994
AvKARE \| Other
Disaggregation of Revenue [Line Items]
Net revenue	$ 9,011	$ 8,708	$ 23,851	$ 22,906